Clinical Trials on Papulosquamous Skin Disease in Switzerland

Total 7515 results

University of Zurich

Withdrawn

Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (DIPSO)

Psoriasis

Switzerland
Immune Technologies & Medicine GmbH

Unknown

Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis

Psoriasis

Switzerland
Ennar Pharmaceuticals AF
University of Zurich

Unknown

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF (EGFR)

Plaque Psoriasis

Switzerland
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Moderate to Severe Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis

Switzerland
University of Zurich

Completed

Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases (PRUVAB)

Psoriasis | Eczema

Switzerland
Prof Curdin Conrad
Centre Hospitalier Universitaire Vaudois

Not yet recruiting

TYK2 Inhibition in Paradoxical Psoriasis (TYPP)

Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis | Candidates for Systemic Therapy for Psoriasis

Switzerland
University of Zurich

Unknown

Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin

Lichen Planus (LP)

Switzerland
Swiss Dermatology Network for Targeted Therapies

Recruiting

Swiss Dermatology Network of Targeted Therapies (SDNTT) (SDNTT)

Psoriasis

Switzerland
Novartis Pharmaceuticals

Completed

Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Psoriasis | Psoriatic Arthritis

Switzerland
Kantonsspital Winterthur KSW

Recruiting

Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus

Lichen Sclerosus

Switzerland
University Hospital Inselspital, Berne
University of Bern

Terminated

Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus

Vulvar Lichen Sclerosus

Switzerland
Novartis Pharmaceuticals

Completed

A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

Plaque Psoriasis, Psoriatic Arthritis

Switzerland
University Hospital Inselspital, Berne
Deka Medical, Inc.

Active, not recruiting

Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis

Lichen Sclerosus Et Atrophicus of the Vulva

Switzerland
Creabilis SA

Completed

CT 327 in the Treatment of Psoriasis Vulgaris

Psoriasis

Switzerland, United States, United Kingdom
University of Zurich

Unknown

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis (APRESCALP)

Psoriasis Vulgaris | Psoriasis of Scalp

Switzerland
University of Zurich

Unknown

Haut-Tief Patient Education on Psoriasis and Eczema

Psoriasis | Atopic Dermatitis/ Eczema

Switzerland
Prof. Dr. Volker Viereck

Active, not recruiting

Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus

Vulvar Lichen Sclerosus | Chronic Skin Disease

Switzerland
University Hospital, Basel, Switzerland
Boehringer Ingelheim

Recruiting

International Rare And Severe Psoriasis Expert Network (IRASPEN)

Pustular Psoriasis (PP)

Germany, Italy, Singapore, Switzerland, Portugal, Turkey
Janssen-Cilag International NV

Recruiting

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (STELARA)

Psoriasis

Belgium, United Kingdom, Austria, Denmark, France, Germany, Netherlands, Norway, Russian Federation, Switzerland, Greece
AbbVie (prior sponsor, Abbott)

Completed

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis (STEPin)

Plaque Psoriasis

Spain, United Kingdom, Estonia, Germany, Bulgaria, Finland, Hungary, Poland, Argentina, Canada, Denmark, Switzerland, Sweden
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

Plaque Psoriasis

Spain, United States, Canada, Germany, Denmark, France, Italy, Switzerland, Austria
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
Actelion

Completed

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Hungary, Italy, Lithuania, Romania, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom
Amgen

Completed

A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice (APPRECIATE)

Psoriasis

Austria, Germany, Switzerland, United Kingdom, Ireland, Spain, Croatia, Czechia, Slovenia, Sweden
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis

Psoriasis

Belgium, France, Germany, Italy, Spain, United Kingdom, Switzerland, Greece, Netherlands, Sweden, Austria, Hungary, Denmark, Norway, Portugal, Turkey, Czech Republic, Finland, Poland
Boehringer Ingelheim

Completed

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

United States, Singapore, Korea, Republic of, Germany, Japan, Malaysia, China, France, Thailand, Tunisia, Switzerland, Taiwan
Biogen

Completed

Safety and Tolerability of Repeat Courses of IM Alefacept

Chronic Plaque Psoriasis

United States, Germany, France, Canada, Austria, Denmark, Netherlands, Switzerland, United Kingdom
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Austria, Belgium, Canada, France, Germany, Poland, Puerto Rico, Spain, Switzerland
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
Amgen

Completed

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life (EMBRACE)

Psoriasis

France, Italy, Spain, United Kingdom, Switzerland, Germany
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more
Abbott

Completed

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Chronic Plaque Psoriasis

Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, Finland, Turkey, Italy, Czech Republic, Austria, Netherlands, United Kingdom, Greece
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Pfizer

Completed

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, France, Hungary, Russian Federation, Singapore, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Hong Kong, Israel, Korea, Republic of, Netherlands, Poland, Slovaki... and more
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Permedica spa

Active, not recruiting

Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica's MIRAI Prosthesis

Psoriatic Arthritis | Shoulder Osteoarthritis | Primary Osteoarthritis | Secondary Osteoarthritis | Avascular Necrosis of Humerus | Rheumatoid Arthritis Shoulder | Cuff Tear Arthropathy | Fracture, Shoulder

Germany, Italy, Switzerland
University of Zurich

Completed

Impact on UVB Narrow Band and UVA1 Therapy on Serum 25-hydroxyvitamin D Levels

Skin Disease

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Centocor, Inc.

Completed

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada, Switzerland, Finland, Denmark
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland

Clinical Trials on Papulosquamous Skin Disease in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations